Symbols / EVLO
EVLO Chart
About
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis . The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.90K |
| Enterprise Value | 16.69M | Income | -82.35M | Sales | — |
| Book/sh | -1.42 | Cash/sh | 0.91 | Dividend Yield | — |
| Payout | 0.00% | Employees | 66 | IPO | — |
| P/E | — | Forward P/E | -0.00 | PEG | — |
| P/S | — | P/B | -0.00 | P/C | — |
| EV/EBITDA | -0.24 | EV/Sales | — | Quick Ratio | 0.43 |
| Current Ratio | 0.48 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -3.91 | EPS next Y | -1.85 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2023-11-09 17:00 | ROA | -83.25% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 18.98M |
| Shs Float | 18.90M | Short Float | 2.22% | Short Ratio | 0.12 |
| Short Interest | — | 52W High | 0.00 | 52W Low | 0.00 |
| Beta | 0.52 | Avg Volume | 804.00 | Volume | 133.00 |
| Target Price | — | Recom | None | Prev Close | $0.00 |
| Price | $0.00 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-41.07
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-10-18 | down | TD Cowen | Outperform → Market Perform | — |
| 2023-07-26 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $10 |
- Flagship-backed microbiome biotech Evelo to shut down - BioPharma Dive Wed, 22 Nov 2023 08
- Evelo Biosciences (EVLO) Stock Price, News & Analysis - MarketBeat Wed, 16 May 2018 16
- Evelo Biosciences (EVLO) Stock Soared 331% on a Patent Award - AskTraders.com Fri, 16 Jun 2023 07
- Why Is Atomera (ATOM) Stock Up 34% Today? - InvestorPlace hu, 27 Apr 2023 07
- EVLO Completes Commissioning of First of Three Energy Storage Projects in American Samoa - Newswire Canada ue, 15 Apr 2025 07
- Trainers And Editors Share The Best Apps For Every Kind Of Exerciser - Yahoo ue, 28 Jan 2025 08
- Will the Gut Microbiome Change Medicine? Wall Street Isn't Convinced. - The Motley Fool ue, 17 Sep 2019 07
- Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga Mon, 12 Oct 2020 12
- Evelo Biosciences Sees Unusually High Options Volume (NASDAQ:EVLO) - Defense World hu, 05 Feb 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| TaxEffectOfUnusualItems | -109.20K | -871.02K |
| TaxRateForCalcs | 0.21 | 0.27 |
| NormalizedEBITDA | -106.34M | -112.69M |
| TotalUnusualItems | -520.00K | -3.23M |
| TotalUnusualItemsExcludingGoodwill | -520.00K | -3.23M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -114.53M | -122.18M |
| ReconciledDepreciation | 2.06M | 2.22M |
| EBITDA | -106.86M | -115.92M |
| EBIT | -108.92M | -118.14M |
| NetInterestIncome | -4.67M | -3.61M |
| InterestExpense | 4.67M | 3.61M |
| NormalizedIncome | -114.12M | -119.82M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -114.53M | -122.18M |
| TotalExpenses | 108.47M | 115.40M |
| TotalOperatingIncomeAsReported | -108.47M | -115.40M |
| DilutedAverageShares | 4.36M | 2.65M |
| BasicAverageShares | 4.36M | 2.65M |
| DilutedEPS | -26.20 | -46.20 |
| BasicEPS | -26.20 | -46.20 |
| DilutedNIAvailtoComStockholders | -114.53M | -122.18M |
| NetIncomeCommonStockholders | -114.53M | -122.18M |
| NetIncome | -114.53M | -122.18M |
| NetIncomeIncludingNoncontrollingInterests | -114.53M | -122.18M |
| NetIncomeContinuousOperations | -114.53M | -122.18M |
| TaxProvision | 930.00K | 428.00K |
| PretaxIncome | -113.60M | -121.75M |
| OtherIncomeExpense | -459.00K | -2.74M |
| OtherNonOperatingIncomeExpenses | 61.00K | 486.00K |
| SpecialIncomeCharges | -520.00K | -3.23M |
| OtherSpecialCharges | 520.00K | 3.23M |
| NetNonOperatingInterestIncomeExpense | -4.67M | -3.61M |
| InterestExpenseNonOperating | 4.67M | 3.61M |
| OperatingIncome | -108.47M | -115.40M |
| OperatingExpense | 108.47M | 115.40M |
| ResearchAndDevelopment | 78.55M | 83.64M |
| SellingGeneralAndAdministration | 29.91M | 31.75M |
| GeneralAndAdministrativeExpense | 29.91M | 31.75M |
| OtherGandA | 10.55M | 12.14M |
| SalariesAndWages | 19.36M | 19.61M |
| TotalRevenue | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 |
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| OrdinarySharesNumber | 5.54M | 2.68M |
| ShareIssued | 5.54M | 2.68M |
| TotalDebt | 51.14M | 56.29M |
| TangibleBookValue | -4.99M | 8.67M |
| InvestedCapital | 38.62M | 55.22M |
| WorkingCapital | 39.18M | 53.66M |
| NetTangibleAssets | -4.99M | 8.67M |
| CapitalLeaseObligations | 7.52M | 9.74M |
| CommonStockEquity | -4.99M | 8.67M |
| TotalCapitalization | 38.62M | 55.22M |
| TotalEquityGrossMinorityInterest | -4.99M | 8.67M |
| StockholdersEquity | -4.99M | 8.67M |
| RetainedEarnings | -529.22M | -414.69M |
| AdditionalPaidInCapital | 524.12M | 423.31M |
| CapitalStock | 111.00K | 54.00K |
| CommonStock | 111.00K | 54.00K |
| PreferredStock | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 69.43M | 79.20M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 57.04M | 61.84M |
| OtherNonCurrentLiabilities | 659.00K | |
| NonCurrentDeferredLiabilities | 7.50M | 7.50M |
| NonCurrentDeferredRevenue | 7.50M | 7.50M |
| LongTermDebtAndCapitalLeaseObligation | 48.88M | 54.34M |
| LongTermCapitalLeaseObligation | 5.26M | 7.79M |
| LongTermDebt | 43.61M | 46.56M |
| CurrentLiabilities | 12.39M | 17.36M |
| OtherCurrentLiabilities | 427.00K | 742.00K |
| CurrentDebtAndCapitalLeaseObligation | 2.26M | 1.95M |
| CurrentCapitalLeaseObligation | 2.26M | 1.95M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.19M | 6.41M |
| PayablesAndAccruedExpenses | 8.52M | 8.26M |
| CurrentAccruedExpenses | 6.75M | 6.66M |
| Payables | 1.76M | 1.60M |
| AccountsPayable | 1.76M | 1.60M |
| TotalAssets | 64.44M | 87.87M |
| TotalNonCurrentAssets | 12.87M | 16.84M |
| OtherNonCurrentAssets | 1.16M | 1.31M |
| NetPPE | 11.71M | 15.53M |
| AccumulatedDepreciation | -9.34M | -7.63M |
| GrossPPE | 21.05M | 23.17M |
| Leases | 2.16M | 2.16M |
| ConstructionInProgress | 1.12M | 1.32M |
| OtherProperties | 9.76M | 9.69M |
| MachineryFurnitureEquipment | 1.14M | 1.09M |
| BuildingsAndImprovements | 6.87M | 8.91M |
| Properties | 0.00 | 0.00 |
| CurrentAssets | 51.57M | 71.03M |
| OtherCurrentAssets | 3.63M | 2.58M |
| PrepaidAssets | 2.58M | |
| CashCashEquivalentsAndShortTermInvestments | 47.94M | 68.44M |
| CashAndCashEquivalents | 47.94M | 68.44M |
| CashEquivalents | 46.66M | 66.99M |
| CashFinancial | 1.28M | 1.45M |
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| FreeCashFlow | -101.86M | -98.24M |
| RepaymentOfDebt | -47.61M | 0.00 |
| IssuanceOfDebt | 44.49M | 14.78M |
| IssuanceOfCapitalStock | 84.54M | 81.75M |
| CapitalExpenditure | -622.00K | -1.52M |
| InterestPaidSupplementalData | 4.22M | 3.38M |
| IncomeTaxPaidSupplementalData | 633.00K | 25.00K |
| EndCashPosition | 49.10M | 69.75M |
| BeginningCashPosition | 69.75M | 70.42M |
| EffectOfExchangeRateChanges | -454.00K | 0.00 |
| ChangesInCash | -20.20M | -666.00K |
| FinancingCashFlow | 81.66M | 97.54M |
| CashFlowFromContinuingFinancingActivities | 81.66M | 97.54M |
| ProceedsFromStockOptionExercised | 234.00K | 1.01M |
| NetCommonStockIssuance | 84.54M | 81.75M |
| CommonStockIssuance | 84.54M | 81.75M |
| NetIssuancePaymentsOfDebt | -3.12M | 14.78M |
| NetLongTermDebtIssuance | -3.12M | 14.78M |
| LongTermDebtPayments | -47.61M | 0.00 |
| LongTermDebtIssuance | 44.49M | 14.78M |
| InvestingCashFlow | -622.00K | -1.48M |
| CashFlowFromContinuingInvestingActivities | -622.00K | -1.48M |
| NetPPEPurchaseAndSale | -622.00K | -1.48M |
| SaleOfPPE | 0.00 | 38.00K |
| PurchaseOfPPE | -622.00K | -1.52M |
| OperatingCashFlow | -101.23M | -96.72M |
| CashFlowFromContinuingOperatingActivities | -101.23M | -96.72M |
| ChangeInWorkingCapital | -9.67M | 2.07M |
| ChangeInOtherWorkingCapital | 7.50M | |
| ChangeInOtherCurrentLiabilities | -3.07M | -2.21M |
| ChangeInPayablesAndAccruedExpense | -5.44M | -2.60M |
| ChangeInAccruedExpense | -5.61M | -2.76M |
| ChangeInPayable | 170.00K | 159.00K |
| ChangeInAccountPayable | 170.00K | 159.00K |
| ChangeInPrepaidAssets | -1.16M | -622.00K |
| OtherNonCashItems | 4.39M | 2.10M |
| StockBasedCompensation | 15.16M | 15.85M |
| DepreciationAmortizationDepletion | 2.06M | 2.22M |
| DepreciationAndAmortization | 2.06M | 2.22M |
| Depreciation | 2.06M | 2.22M |
| OperatingGainsLosses | 1.35M | 3.22M |
| NetForeignCurrencyExchangeGainLoss | 412.00K | 0.00 |
| GainLossOnSaleOfPPE | 422.00K | -7.00K |
| NetIncomeFromContinuingOperations | -114.53M | -122.18M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for EVLO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|